The top end of town might not be where most market watchers turn to hunt down whopping returns, but some brokers appears hopeful the share price of $139 billion giant CSL Limited (ASX: CSL) could break the mould.

Indeed, they’ve tipped the S&P/ASX 200 Index (ASX: XJO) healthcare icon to soar as much as 22% from its current levels. That’s on top of the 8.5% gain it’s posted over the last 12 months.

Right now, the CSL share price is trading at $286.40. That’s 0.49% higher than its previous close.

For comparison, the ASX 200 has lifted 0.88% today and dropped 4% since this time last year.

So, what might the future hold for the CSL share price? Let’s take a look at what these bullish brokers are forecasting.

Is the CSL share price a buy right now?

There’s a lot to like about CSL shares, according to these experts.

The biotech icon impressed with the release of its first-half earnings last month. It posted a 19% jump in revenue, a 10% improvement in post-tax profit prior to amortisation on a constant currency basis, and lifted its dividend to US$1.07 per share.

It also revealed record plasma collections – a factor that could boost its revenue further in the future, Citi noted.

The broker retained its buy rating and forecast the stock to gain a notable 22% to $350 on the back of its results, my Fool colleague James reported.

Meanwhile, Morgans tips the company’s earnings to continue growing in the coming years as its interest expenses fall and sales at its Behring and Vifor businesses rise.

The broker has a $337.92 price target – a potential 18% gain – and an add rating on CSL shares.

Though, not all are convinced the ASX 200 healthcare monolith represents a good buy right now.

Goldman Sachs has a neutral rating and a $314 price target on the share. Though, that still represents a 9% upside.

The post Does the CSL share price really offer 22% upside right now? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• How I’d aim to retire rich enough to live on passive income from my ASX dividend shares
• Analysts say these ultra high quality blue chip ASX 200 shares are buys
• Why is the CSL share price smashing the ASX 200 on Thursday?
• Here’s how much I’d need to invest in CSL shares to generate a $300 monthly income
• 5 ASX 200 shares that inflation can’t touch: expert

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/DtZM5fR

• Stock Market